Follow along on our guide to Multiple Myeloma, a cancer of the bone marrow's infection-fighting plasma cells. As cancerous ...

After being diagnosed with multiple myeloma, Valarie Traynham turned her journey into a mission—raising awareness, educating ...

Discover how ctDNA revolutionizes multiple myeloma monitoring, tracking disease progression, and improving personalized ...

SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, and inflammatory and infectious diseases, announces the publication of ...

Kangpu Biopharma receives China NMPA’s IND approval for KPG-818 to treat relapsed/refractory multiple myeloma: Hefei, China Saturday, March 1, 2025, 14:00 Hrs [IST] Kangpu Bioph ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

Multiple myeloma is a rare type of blood cancer that starts in your plasma cells. Your plasma cells are a type of white blood cell inside your bone marrow, the soft inner part of your bones.

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells.

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...